Pipeline
Our Pipeline is comprised of Biologics, including the proprietary BEAT® MultispecificsTM platform, targeting the spectrum of immune cell engagement and indications across hematologic and solid tumors. If you are interested in exploring a partnership, Contact us
Diversity of Immune Cell Engagement in Autoimmune Diseases and Across Hematologic & Solid Tumor Indications
| ONCOLOGY ASSET | DESCRIPTION | INDICATION |
|---|---|---|
| DISCOVERY | PRECLINICAL | PHASE 1 | PHASE 2 | PHASE 3 |
|---|---|---|---|---|
| RIGHTS |
|---|
(ABBV-2001)
CD38 x BCMA x CD3 Trispecific
Multiple Myeloma
*
ISB 2301
Multispecific immune cell activator
Solid Tumors
ISB 2302
Bispecific immune modulator
Hematologic & Solid Tumors
ISB 2501
Trispecific T-cell engager
Solid Tumors
*IGI will partner with Glenmark to develop, manufacture, and commercialize ISB 2001/ABBV-2001 in all territories outside AbbVie’s licensed markets
| IMMUNOLOGY ASSET | DESCRIPTION | INDICATION |
|---|---|---|
| DISCOVERY | PRECLINICAL | PHASE 1 | PHASE 2 | PHASE 3 |
|---|---|---|---|---|
| RIGHTS |
|---|
ISB 880 (LAD191)
IL-1RAP antagonist mAb
Hidradenitis Suppurativa
Telazorlimab
(ISB 830)
(ISB 830)
ISB 830-X8
(STAR-0310)
OX40 antagonist mAb
Atopic Dermatitis
Oncology
Immunology
PRODUCTS
ONCOLOGY ASSET
DESCRIPTION
CD38 x BCMA x CD3 Trispecific
INDICATION
Multiple Myeloma
PHASE
RIGHTS
*
PRODUCTS
ONCOLOGY ASSET
ISB 2301
DESCRIPTION
Multispecific immune cell activator
INDICATION
Solid Tumors
PHASE
RIGHTS
PRODUCTS
ONCOLOGY ASSET
ISB 2302
DESCRIPTION
Bispecific immune modulator
INDICATION
Hematologic & Solid Tumors
PHASE
RIGHTS
PRODUCTS
ONCOLOGY ASSET
ISB 2501
DESCRIPTION
Trispecific T -cell engager
INDICATION
Solid Tumors
PHASE
RIGHTS
PRODUCTS
IMMUNOLOGY ASSET
ISB 880 (ALM27134)
DESCRIPTION
IL-1RAP antagonist mAb
INDICATION
Hidradenitis Suppurativa
PHASE
RIGHTS
PRODUCTS
IMMUNOLOGY ASSET
Telazorlimab (ISB 830)
DESCRIPTION
OX40 antagonist mAb
INDICATION
Atopic Dermatitis
PHASE
RIGHTS
PRODUCTS
IMMUNOLOGY ASSET
ISB 830-X8 (STAR-0310)
DESCRIPTION
OX40 antagonist mAb
INDICATION
Atopic Dermatitis
PHASE
RIGHTS